Type:50mg vial
Generic Name:Doxorubicin Hydrochloride
Manufacturer:Beacon Pharmaceuticals Ltd.
Price:৳1000.00
AIDS-related Kaposi's sarcoma, Ovarian carcinoma, Metastatic breast carcinoma, bladder carcinoma
Intravenous As Doxorubicin liposomal Kaposi's Sarcoma Indicated for AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy 20 mg/m² IV q3Weeks Ovarian Cancer Indicated for ovarian cancer in patients whose disease has progressed or recurred after platinum-based chemotherapy 50 mg/m² IV q4Weeks x 4 courses minimum Multiple Myeloma Indicated in combination with bortezomib for multiple myeloma in patients who have not previously received bortezomib and have received at least 1 prior therapy 30 mg/m² IV on day 4 following bortezomib 1.3 mg/m² on days 1, 4, 8 & 11 q3Weeks Metastatic breast cancer Adult: 60-75 mg/m2 BSA once every 3 wk in combination with cyclophosphamide given as an infusion over 1 hr diluted in 0.9% sodium chloride or 5% glucose. Irrigation Local malignant neoplasms in the bladder Adult: 50 ml of a 1 mg/ml solution instilled into the bladder for 1 hr once a mth. Hepatic Impairment Serum bilirubin <1.2 mg/dL: Dose adjustment not necessary Serum bilirubin 1.2-3 mg/dL [20.5-51.3 micromoles/L]: Give 50% dose Serum bilirubin: 3.1-5 mg/dL [53-85.5 micromoles/L]: Give 25% dose Severe hepatic impairment: Contraindicated
Safety and efficacy not established
Renal Impairment Dose adjustment not necessary
Cardiac disease, neonates, pregnancy and lactation, prior irradiation to mediastinum. IM/SC admin. Severe myelosuppression due to previous treatment with antitumour agents or radiotherapy.
Doxorubicin is a cytotoxic anthracycline antibiotic. The cytotoxic action results from its binding to DNA and inhibition of nucleic acid synthesis. Doxorubicin has been shown to produce regression in a variety of disseminated malignancies.
Elderly, children, hepatic impairment. Monitor blood counts and ECG. Lactation: Enters breast milk/not recommended
>10% Kaposi's Sarcoma Anemia (>50%),Thrombocytopenia (>50%),Neutropenia (10-50%),Anemia (18.2%),Nausea (17%) Ovarian cancer >25% Hand-foot syndrome (50%),Nausea (46%),Stomatitis (41%),Asthenia (40.2%),Vomiting (32.6%),Rash (28%),Constipation (>25%),Abdominal pain (>25%) Ovarian cancer 10-25% Fever (21.3%),Anorexia (20%),Diarrhea (20%),Peripheral edema,Dyspepsia,Pharyngitis,Dyspnea,Alopecia 1-10% Kaposi's Sarcoma 5-10% Asthenia (9.9%),Fever (9.1%),Diarrhea (7.8%),Vomiting (7.8%),Stomatitis (6.8%),Rash (1-5%),Alopecia (1-5%),Increased alkaline phosphatase Kaposi's Sarcoma 1-5% Hand-foot syndrome (3.4%),Hypotension,Tachycardia,Dyspnea,Hemolysis,Rash Ovarian cancer (selected) Neutropenia (13.3%),Anemia (0.4-5.4%),Thrombocytopenia (1.3%) <1% Abscess,Acute myeloid leukemia,Cardiomegaly,Cardiomyopathy,Erythema nodosum,Hyperkalemia,Hyperuricemia,Ketosis Potentially Fatal: Bone marrow suppression, cardiotoxicity.
Pregnancy Category: D Lactation: Enters breast milk/not recommended
Doxorubicin interacts with a number of other drugs e.g. antibiotics (aminoglycosides), steroids, aminophylline and propranolol. Potentially Fatal: Cholestasis induced by mercaptopurine may be potentiated by concurrent administration of the drug. Toxicity may be increased if streptozocin is given concurrently.
